Urethral cancer overview: Difference between revisions

Jump to navigation Jump to search
Shanshan Cen (talk | contribs)
No edit summary
Shanshan Cen (talk | contribs)
No edit summary
Line 19: Line 19:
Urethral cancer is a rare disease that tends to affect African Americans. The incidence is approximately 0.43 per 100,000 in the united states for men, and approximately 0.15 per 100,000 for women.
Urethral cancer is a rare disease that tends to affect African Americans. The incidence is approximately 0.43 per 100,000 in the united states for men, and approximately 0.15 per 100,000 for women.


==Risk Factors==
The risk factors of urethral cancer include history of [[bladder cancer]], [[urinary tract infections]], and [[sexually transmitted diseases]].


==Prognosis==
The prognosis varies with the depth of invasion, anatomical location, size, and stage of [[tumor]]. Superficial tumors located in the [[distal urethra]] have the most favorable [[prognosis]].


==Staging==
The staging of urethral cancer is based on the TNM system. Moreover, it may be classified into 5 subtypes based on the depth of invasion.
==History and Symptoms==
Symptoms of urethral cancer include [[hematuria]], [[urinary hesitancy]], [[frequent urination]], [[incontinence]],  [[swelling]] in the groin, and a lump or thickness in the perineum or penis.
==Laboratory Findings==
Laboratory findings consistent with the diagnosis of urethral cancer include abnormal cells in urine cytology and blood in [[urinalysis]].
==Other Diagnostic Studies==
Other diagnostic studies for urethral cancer include [[ureteroscopy]] and [[biopsy]].
==Medical Therapy==
The predominant therapy for urethral cancer is surgical resection. Adjunctive [[chemotherapy]] or [[radiation therapy]] may be required. The optimal therapy depends on the stage at diagnosis and the anatomic location of the tumor.
==Surgery==
Surgery is the mainstay of treatment for urethral cancer. However, it is not recommended among patients with metastatic urethral cancer.


==References==
==References==

Revision as of 19:35, 8 September 2015

Urethral cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethral cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethral cancer overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethral cancer overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Urethral cancer overview

CDC on Urethral cancer overview

Urethral cancer overview in the news

Blogs on Urethral cancer overview

Directions to Hospitals Treating Urethral cancer

Risk calculators and risk factors for Urethral cancer overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Urethral cancer is a rare type of cancer originating from the urethra. It is more common in women than in men. Types of urethral cancer include transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. It is also a disease in which cancer cells form in the tissues of the urethra.

Classification

Urethral cancer may be classified according to cell typies into 3 subtypes: transitional cell, squamous cell, and adenocarcinoma. It may also be classified into distal urethral cancer, proximal urethral cancer and urethral cancer associated with invasive bladder cancer.

Causes

Urethral cancer may be caused by an infection of human papillomavirus.

Differential diagnosis

Urethral cancer must be differentiated from bladder cancer, cervical cancer, bladder stones, ureteral stones, cystitis, neurogenic bladder, and urethritis.

Epidemiology and Demographics

Urethral cancer is a rare disease that tends to affect African Americans. The incidence is approximately 0.43 per 100,000 in the united states for men, and approximately 0.15 per 100,000 for women.

Risk Factors

The risk factors of urethral cancer include history of bladder cancer, urinary tract infections, and sexually transmitted diseases.

Prognosis

The prognosis varies with the depth of invasion, anatomical location, size, and stage of tumor. Superficial tumors located in the distal urethra have the most favorable prognosis.

Staging

The staging of urethral cancer is based on the TNM system. Moreover, it may be classified into 5 subtypes based on the depth of invasion.

History and Symptoms

Symptoms of urethral cancer include hematuria, urinary hesitancy, frequent urination, incontinence, swelling in the groin, and a lump or thickness in the perineum or penis.

Laboratory Findings

Laboratory findings consistent with the diagnosis of urethral cancer include abnormal cells in urine cytology and blood in urinalysis.

Other Diagnostic Studies

Other diagnostic studies for urethral cancer include ureteroscopy and biopsy.

Medical Therapy

The predominant therapy for urethral cancer is surgical resection. Adjunctive chemotherapy or radiation therapy may be required. The optimal therapy depends on the stage at diagnosis and the anatomic location of the tumor.

Surgery

Surgery is the mainstay of treatment for urethral cancer. However, it is not recommended among patients with metastatic urethral cancer.

References